Assess the data and tweets to estimate whether the closing price of $sny will escalate or deflate at 2015-06-18. Respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2015-06-04,0.6,2.3,-0.3,-0.4,-0.4,-1.6,-1.2,-0.9,-1.3,-1.7,-1.7
2015-06-05,-0.1,0.7,-0.6,-2.6,-2.6,1.1,1.1,1.6,1.4,1.0,0.9
2015-06-08,0.0,0.2,-0.4,-0.1,-0.1,1.4,1.0,1.6,1.5,1.1,1.0
2015-06-09,-0.0,0.4,-0.9,-0.1,-0.1,1.4,1.2,1.6,1.6,1.2,1.1
2015-06-10,-1.4,0.2,-1.8,2.4,2.4,-1.2,-1.2,-0.8,-0.7,-1.0,-1.2
2015-06-11,-0.3,0.5,-0.8,1.1,1.1,-2.2,-2.1,-1.9,-1.6,-1.9,-2.2
2015-06-12,-1.0,0.0,-1.6,-1.1,-1.1,-0.7,-0.8,-0.8,-0.5,-0.7,-1.0
2015-06-15,-0.3,0.1,-0.9,-2.3,-2.3,1.6,1.6,1.3,1.7,1.6,1.3
2015-06-16,-0.0,0.4,-0.4,-0.4,-0.4,2.0,1.9,1.8,2.0,2.0,1.7
2015-06-17,0.1,0.2,-1.2,-0.8,-0.8,2.1,2.3,2.4,2.7,2.8,2.6

2015-06-07: a big step for this tiny biotech that's targeting rare diseases $fold $shpg $sny :  via AT_USER
2015-06-08: #fda phones a friend:  implications for $amg, $regn, $sny.|AT_USER it would be bad for $sny, $regn, and $amgn! and good for $pfe.
2015-06-09: trading in regeneron halted pending ad comm news later today  #premarket $regn $sny|#fda roberts: changes in glucose/homeostasis are monitorable &amp; treatable #emdac #praluent #pcsk9 $sny $regn|icym
2015-06-10: rt AT_USER fda adcom votes 11-4 in support of approval of $amgn's repatha, now discussion as to which patient populations $regn $sny
2015-06-12: rt AT_USER pcsk9 panels: nissen's take  #fda #emdac $amgn $sny $regn $pfe #pharma #pcsk9
2015-06-16: jefferies analyst jeffrey holford target revisions: sanofi $sny to €96 from €100; eli lilly $lly to $100 from $87.
Answer:
Assess the data and tweets to estimate whether the closing price of $sny will escalate or deflate at 2015-06-18. Respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2015-06-04,0.6,2.3,-0.3,-0.4,-0.4,-1.6,-1.2,-0.9,-1.3,-1.7,-1.7
2015-06-05,-0.1,0.7,-0.6,-2.6,-2.6,1.1,1.1,1.6,1.4,1.0,0.9
2015-06-08,0.0,0.2,-0.4,-0.1,-0.1,1.4,1.0,1.6,1.5,1.1,1.0
2015-06-09,-0.0,0.4,-0.9,-0.1,-0.1,1.4,1.2,1.6,1.6,1.2,1.1
2015-06-10,-1.4,0.2,-1.8,2.4,2.4,-1.2,-1.2,-0.8,-0.7,-1.0,-1.2
2015-06-11,-0.3,0.5,-0.8,1.1,1.1,-2.2,-2.1,-1.9,-1.6,-1.9,-2.2
2015-06-12,-1.0,0.0,-1.6,-1.1,-1.1,-0.7,-0.8,-0.8,-0.5,-0.7,-1.0
2015-06-15,-0.3,0.1,-0.9,-2.3,-2.3,1.6,1.6,1.3,1.7,1.6,1.3
2015-06-16,-0.0,0.4,-0.4,-0.4,-0.4,2.0,1.9,1.8,2.0,2.0,1.7
2015-06-17,0.1,0.2,-1.2,-0.8,-0.8,2.1,2.3,2.4,2.7,2.8,2.6

2015-06-07: a big step for this tiny biotech that's targeting rare diseases $fold $shpg $sny :  via AT_USER
2015-06-08: #fda phones a friend:  implications for $amg, $regn, $sny.|AT_USER it would be bad for $sny, $regn, and $amgn! and good for $pfe.
2015-06-09: trading in regeneron halted pending ad comm news later today  #premarket $regn $sny|#fda roberts: changes in glucose/homeostasis are monitorable &amp; treatable #emdac #praluent #pcsk9 $sny $regn|icym
2015-06-10: rt AT_USER fda adcom votes 11-4 in support of approval of $amgn's repatha, now discussion as to which patient populations $regn $sny
2015-06-12: rt AT_USER pcsk9 panels: nissen's take  #fda #emdac $amgn $sny $regn $pfe #pharma #pcsk9
2015-06-16: jefferies analyst jeffrey holford target revisions: sanofi $sny to €96 from €100; eli lilly $lly to $100 from $87.
Answer:+Rise